Clinical Trials Browser

Has results × Urinary Bladder Neoplasms × Erlotinib Hydrochloride × Clear all

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Phase 2 Completed

673 enrolled 22 charts

GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT00749892 2020-09-10

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

Phase 2 Completed

34 enrolled 9 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT02169284 2020-07-07

Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery

Phase 2 Terminated

50 enrolled 27 charts

Urinary Bladder Neoplasms

NCT00380029 2017-07-19

Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer

Phase 2 Completed

27 enrolled 12 charts

Urinary Bladder Neoplasms